Form 4: Lisata Therapeutics Exec Boosts Equity, Options

Lisata Therapeutics' SVP, Tariq Imam, acquired 15,000 restricted stock awards and 7,000 stock options, while also disposing of shares for tax liabilities.

Summary

• Tariq Imam, SVP, Business Development, and General Counsel at Lisata Therapeutics, Inc. (LSTA), reported equity transactions on January 9, 2026.
• Acquired 15,000 restricted stock awards at a price of $0 under the Issuer's 2018 Equity Incentive Compensation Plan. These awards vest in four equal installments, with one-fourth vesting immediately on the grant date and an additional one-fourth vesting on each of the first, second, and third annual anniversaries of the grant date.
• Acquired 7,000 stock options with an exercise price of $1.97. These options also vest in four equal installments, with one-fourth vesting immediately on the grant date and an additional one-fourth vesting on each of the first, second, and third anniversaries of the grant date. The options have an expiration date of January 9, 2036.
• Disposed of a total of 3,501 shares of common stock at $1.97 per share. These shares were withheld as payment for tax liabilities incurred upon the vesting of restricted stock.
• Following these reported transactions, beneficial ownership of common stock is 36,078 shares, which includes 17,750 unvested restricted stock.
• Beneficial ownership of derivative securities (stock options) is 7,000 options.

Sentiment

Score: 6

Explanation: The filing reports routine executive equity compensation, including grants of restricted stock and stock options, which aligns management incentives with long-term company performance. The disposal of shares for tax purposes is a standard event.

Positives

• An executive, Tariq Imam, received a significant grant of 15,000 restricted stock awards and 7,000 stock options, indicating continued alignment with shareholder interests and potential confidence in future performance.
• The vesting schedule for both restricted stock and options (over three years with immediate vesting of one-fourth) suggests a long-term retention strategy for key management.

Negatives

• The disposal of 3,501 shares of common stock to cover tax liabilities, while a standard practice, represents a reduction in the executive's direct shareholding.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance beyond the vesting schedules and option expiration date for the granted equity.

Industry Context

This is an insider transaction filing, which typically does not provide broader industry context. It reflects internal compensation and equity management for a biotechnology company, aligning executive incentives with long-term company performance.

Comparison to Industry Standards

• The grant of restricted stock and stock options to executives is a standard practice in the biotechnology and pharmaceutical industry to align management incentives with long-term company performance and shareholder value.
• The vesting schedule (four equal installments over three years) is typical for executive equity compensation plans, promoting retention and sustained performance.
• The practice of withholding shares to cover tax liabilities upon vesting of restricted stock is a common and standard procedure across all industries for equity compensation.

Stakeholder Impact

• Shareholders: The executive's increased equity stake through restricted stock and options aligns their interests with shareholders, potentially fostering long-term value creation.
• Employees: This filing specifically pertains to an executive's compensation and does not directly impact the broader employee base, though it reflects the company's compensation strategy for key personnel.

Next Steps

• Future vesting events for the restricted stock awards on the first, second, and third annual anniversaries of January 9, 2026.
• Future vesting events for the stock options on the first, second, and third annual anniversaries of January 9, 2026.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation in the form of restricted stock and stock options, along with standard tax-related share disposals. It does not provide new operational or financial performance data that would warrant a change in investment recommendation. The executive's increased equity stake is a positive for alignment but not a strong catalyst for a 'buy' recommendation on its own.

Keywords

Lisata Therapeutics, LSTA, SEC Form 4, Insider Trading, Restricted Stock, Stock Options, Equity Incentive Plan, Tariq Imam, Executive Compensation